
Ensurge Micropower ASA - Employee Share Purchase Plan
The board of directors of Ensurge Micropower ASA (the “Company”) has on 3 September 2023 resolved to issue 12,771,031 ordinary shares at NOK 0.10 per share to employees and contractors (“Participants”) in the Company who participate in the Company's 2023 Employee Share Purchase Plan (“ESPP”). The ESPP was approved by the annual general meeting on 24 May 2023.
15 Participants participated in the ESPP in this period. The Participants have elected to invest a part of the base salary or service fee in ordinary shares in the Company. Purchase takes place every six months.
Following the issue, also having considered the share issuances in connection with the completed subsequent offering, and the conversion of convertible loans, both announced by the Company on 31 August 2023, the Company's share capital will be NOK 185,968,885.80 divided into 1,859,688,858 shares, each with a nominal value of NOK 0.10.
Primary insiders
Ensurge Micropower ASA discloses transactions by the following primary insiders in Ensurge Micropower ordinary shares:
- Lars Eikeland, CEO and CFO, acquired 2,103,858 ordinary shares at NOK 0.10 per share; and
- Arvind Kamath, EVP Technology Development, acquired 1,770,540 ordinary shares at NOK 0.10 per share.
Please see the enclosed forms for further details on the transactions.
Ensurge Micropower ASA 2023 ESPP
The ESPP was approved at the annual general meeting on 24 May 2023. The ESPP is available on the Company’s website. https://ensurge.com/wp-content/uploads/2023/05/Ensurge-2023-Employee-Share-Purchase-Plan.pdf
Any person who is an eligible participant has been offered to subscribe for shares in the Company in connection with the ESPP. The ESPP is structured around two offering periods, starting on the first day of the calendar month following each planned public disclosure on Oslo Børs of the half-yearly and fourth quarter financial results of the Company, such calendar months being September through February and March through August, with the first offering period however having commenced as of 15 May 2023 and having continued through 31 August 2023. During each offering period, a fixed amount (up to 20% of the employee's gross (pre-tax) base salary or, in the case of contractors, up to 20% of the service fee payable to such contractor) is withheld from the employee's net salary or from the contractor’s service fee, which fixed amount must be at least a total of NOK 6,000 (or equivalent foreign currency) for each offering period. The Participant may sign up to participate in the ESPP from the date of the public disclosure of the half-yearly or fourth quarter financial results until the day before the commencement of the offering period. Unless the Participant actively withdraws from the ESPP, participation is automatically renewed for the same amount for subsequent offering periods. The board's resolution to issue new shares in connection with the ESPP is made pursuant to the authorization granted by the Company's annual general meeting on 24 May 2023 to increase the Company's share capital in connection with the ESPP. Settlement of the subscription amount is made by set-off against debt to the employees and contractors (offset).
In accordance with Regulation (EU) 2017/1129 (the "Prospectus Regulation") Article 1 (5) h, issuance of shares in connection with the ESPP is exempt from the obligation to publish a listing prospectus.
About Ensurge Micropower:
Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The Company's state-of-the-art manufacturing facility, located in the heart of Silicon Valley, combines patented process technology and materials innovation with the scale of roll-to-roll production methods to bring the advantages of Ensurge technology to established and expanding markets.
For more information, please contact:
Terje Rogne, Chairman
Phone: +47 472 02 200
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Changes in Sampo Group Executive Committee and Board of Directors1.10.2023 11:05:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2023 at 12:05 pm Changes in Sampo Group Executive Committee and Board of Directors Following the completion of the partial demerger of Sampo plc, the Sampo Group Executive Committee (GEC) terms of Patrick Lapveteläinen, former Sampo Group CIO, and Petri Niemisvirta, CEO of Mandatum, have ended. Meanwhile, the new Sampo Group CIO Ville Talasmäki has joined the GEC today. Lapveteläinen and Niemisvirta have moved to Mandatum plc, a new company established in connection with the demerger to take up roles as Full-time Chair of the Board and CEO, respectively. Both Patrick Lapveteläinen and Petri Niemisvirta were members of Sampo GEC since 2001. Following the changes, the strength of the GEC has decreased from seven to six members. As previously communicated, the number of the members of the Board of Directors of Sampo has declined from ten to nine as Johanna Lamminen has left the Board as of today. Lamminen, who has been a member of the Sampo Board
Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki1.10.2023 11:00:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 1 October 2022 at 12:00 pm NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA OR SINGAPORE OR ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Partial demerger of Sampo completed - Mandatum to be listed on Nasdaq Helsinki The completion of Sampo plc’s partial demerger has today been registered with the Finnish Trade Register and Mandatum has consequently been separated from Sampo Group, in accordance with the decision of Sampo’s Annual General Meeting on 17 May 2023. Nasdaq Helsinki has admitted the shares in Mandatum plc, the company incorporated in the demerger, to trading on the official list from 2 October 2023. - By separating Mandatum from Sampo, we have simplified the Group and created two entities that are well placed to create shareholder value. Sampo becomes a pure P&C insurance group, while Mandatum i
Redomiciliation to Bermuda completed30.9.2023 16:28:35 CEST | Press release
The Hague, September 30, 2023 - Aegon’s Extraordinary General Meeting of shareholders (EGM) today approved the cross-border conversion into a Bermuda Limited company. After the completion of the EGM, the change of Aegon’s legal seat to Bermuda has been effectuated, as a result of which the company became a Bermuda entity: Aegon Ltd. As of October 1, 2023, the Bermuda Monetary Authority will be Aegon’s group supervisor. Aegon shares will continue to be listed on Euronext Amsterdam (AGN) and NYSE (AEG). As at market open on October 2, 2023, trading will commence in Aegon Ltd. shares. The identifiers (such as the ISIN) of the Aegon shares will change: the Aegon Ltd. common shares will have the ISIN BMG0112X1056; andthe Aegon Ltd. common shares held in New York registry form will have the ISIN US0076CA1045 and the CUSIP 0076CA 104.1 More information on the redomiciliation, as well as the documentation relating to it, can be found here. Contacts Media relations Investor relations Richard Ma
Vow ASA: Order received to double production capacity at VGM’s Follum factory30.9.2023 12:00:00 CEST | Press release
On September 30th, 2023, Vow ASA announced that it has received an order from Vow Green Metals AS to enhance the production capacity at their biocarbon production plant in Hønefoss, Norway. This order is an extension of the equipment order received in October 2021, resulting in a new total contract value of NOK 332 million. In addition to some modification on the original equipment order, the expansion will involve the addition of a new process line, effectively doubling the factory's capacity. This will enable the production of up to 20,000 tons of biocarbon annually. The increased capacity is made possible by utilizing self-sufficient renewable gas to power the new reactor technology developed and manufactured by Vow's subsidiary, C. H. Evensen Industriovner AS. This ensures that the expanded capacity remains within the site's power supply limits. Henrik Badin, CEO of Vow ASA, expressed enthusiasm for this solution, emphasizing its ability to enhance efficiency, significantly increas
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®29.9.2023 22:06:00 CEST | Press release
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United States FDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA. The TOFIDENCE intravenous formulation is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and systemic juvenile idiopathic arthritis. TOFIDENCE is the first tocilizumab biosimilar approved in the United States. Biosimilars are biologic products that have been demonstrated to have equivalent efficacy and comparable safety as the approved reference product, with the advantage that they may offer cost savings and promote